Association of the Estrogen Receptors Beta Expression with the Ki-67 Proliferative Index in Breast Cancer

Background. Estrogen receptors beta (ERβ) are an important biological regulator and target of antiestrogens, however, unlike estrogen receptors alpha (ERɑ), their significance in the prognosis and treatment of breast cancer remains unclear. Purpose. Evaluation of the ERβ prognostic value in the comparative assessment of frequency and level of the marker expression in groups with good and poor prognosis by Ki-67 proliferative index score in breast cancer. Methods. ERβ expression level (% of cells expressing the marker) in 68 breast tissue samples was quantified by immunofluorescence and flow cytometry. Primary antibodies to ERβ (clone 14C8, ab288) and secondary antibodies conjugated with DyLight650 (ab98729) were used. In the same samples, the Ki-67 expression level was assessed by the immunohistochemical method. Results. The ERβ and Ki-67 were detected in 100% breast tissue samples with high heterogeneity of the markers’ expression in different patients. Statistical analysis of good and poor prognosis in accordance with the Ki-67 proliferative index score (Ki-67≤20% and Ki-67>20%) showed the prognostic value of the ERβ expression level of 50%. There was no association between the Ki-67 and ERβ expression levels in the same tumor sample (Spearman's rank correlation coefficient R=–0,16; P>0,05). At the same time, high expression of ERβ≥50% was 2,3 times more frequently detected in the good vs poor prognostic group by Ki-67 — 41% vs 18%, P=0,02. Conclusion. The ERβ expression level ≥50% in the tumor can be considered as a factor of good prognosis of breast cancer.

1. Smolarz B., Nowak A.Z., Romanowicz H. Breast Cancer-Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers (Basel). 2022; 14 (10): 2569. doi: 10.3390/cancers14102569.

2. Tyulyandin S.A., Artamonova E.V., Zhukova L.G., Kislov N.V., Koroleva I.A., Parokonnaya A.A. i dr. Prakticheskie rekomendatsii po lekarstvennomu lecheniyu raka molochnoi zhelezy. Zlokachestvennye opukholi: Prakticheskie Rekomendatsii RUSSCO. 2022; 12 (3s2): 155–197. doi: https://doi.org/10.18027/2224-5057-2022-12-3s2-155-197. (in Russian)

3. Kuiper G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A. 1996; 93 (12): 5925–5930. doi: 10.1073/pnas.93.12.5925.

4. Božović A., Mandušić V., Todorović L., Krajnović M. Estrogen receptor beta: the promising biomarker and potential target in metastases. Int J Mol Sci. 2021; 22 (4): 1656. doi: 10.3390/ijms22041656.

5. Nilsson S., Mäkelä S., Treuter E., Tujague M., Thomsen J., AnderssonG. et al. Mechanisms of estrogen action. Physiol Rev. 2001; 81 (4): 1535–1565. doi: 10.1152/physrev.2001.81.4.1535.

6. Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J. et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007; 87 (3): 905–931. doi: 10.1152/physrev.00026.2006.

7. Warner M., Fan X., Strom A., Wu W., Gustafsson J.Å. 25 years of ERβ: a personal journey. J Mol Endocrinol. 2021; 68 (1): R1–R9. doi: 10.1530/JME-21-0121.

8. Udovicic-Gagula D., Ahmovic A., Bilalovic N., Doric M. Expression of Ki-67 and estrogen receptor beta in primary cutaneous melanoma as a potential indicator of regional lymph node positivity. Appl Immunohistochem Mol Morphol. 2019; 27 (1): 27–32. doi: 10.1097/PAI.0000000000000530.

9. Grover S.K., Agarwal S., Gupta S., Wadhwa N., Sharma N. Expression of estrogen receptor β and Ki 67 in benign & malignant human prostate lesions by immunohistochemistry. Pathol Oncol Res. 2015; 21 (3): 651–657. doi: 10.1007/s12253-014-9870-y.

10. Fujimura T., Takahashi S., Urano T., Ogawa S., Ouchi Y., Kitamura T. et al. Differential expression of estrogen receptor beta (ERbeta) and its C-terminal truncated splice variant ERbetacx as prognostic predictors in human prostatic cancer. Biochem Biophys Res Commun. 2001; 289 (3): 692–699. doi: 10.1006/bbrc.2001.6038.

11. Ström A., Hartman J., Foster J.S., Kietz S., Wimalasena J., Gustafsson J.A. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D [published correction appears in Proc Natl Acad Sci U S A. 2006 May 23; 103 (21): 8298. Proc Natl Acad Sci U S A. 2004; 101 (6): 1566–1571. doi: 10.1073/pnas.0308319100.

12. Thomas C., Gustafsson J.Å. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer. 2011; 11 (8): 597–608. doi: 10.1038/nrc3093.

13. Tan W., Li Q., Chen K., Su F., Song E., Gong C. Estrogen receptor beta as a prognostic factor in breast cancer patients: A systematic review and meta-analysis. Oncotarget. 2016; 7 (9): 10373–10385. doi: 10.18632/oncotarget.7219.

14. Mann S., Laucirica R., Carlson N., Younes P.S., Ali N., Younes A. et al. Estrogen receptor beta expression in invasive breast cancer. Hum Pathol. 2001; 32 (1): 113–118. doi: 10.1053/hupa.2001.21506.

15. Nakopoulou L., Lazaris A.C., Panayotopoulou E.G., Giannopoulou I., Givalos N., Markaki S. et al. The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol. 2004; 57 (5): 523–528. doi: 10.1136/jcp.2003.008599.

16. Maehle B.O., Collett K., Tretli S., Akslen L.A., Grotmol T. Estrogen receptor beta — an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer? APMIS. 2009; 117 (9): 644–650. doi: 10.1111/j.1600-0463.2009. 02510.x.

17. Zhang H., Zhang Z., Xuan L., Zheng S., Guo L., Zhan Q. et al. Evaluation of ER-ɑ , ER-B1 and ER-B2 expression and correlation with clinicopathologic factors in invasive luminal subtype breast cancers. Clin Transl Oncol. 2012; 14 (3): 225–231. doi: 10.1007/s12094-012-0788-0.

18. Liu J., Guo H., Mao K., Zhang K., Deng H., Liu Q. Impact of estrogen receptor-β expression on breast cancer prognosis: a meta-analysis. Breast Cancer Res Treat. 2016; 156 (1): 149–162. doi: 10.1007/s10549-016-3721-3.

19. Guo L., Zhu Q., Yilamu D., Jakulin A., Liu S., Liang T. Expression and prognostic value of estrogen receptor beta in breast cancer patients. Internt J Clin Exp Med. 2014; 7 (10): 3730–3736.

20. Guo L., Zhu Q., Aisimutuola M., Yilamu D., Liu S., Jakulin A. Expression and prognostic value of estrogen receptor β in patients with triple-negative and triple-positive breast cancer. Experimental and therapeutic medicine. 2015; 9 (6): 2147–2150. doi: 10.3892/etm.2015.2380.

21. Guo L., Zhang Y.U., Yilamu D., Liu S., Guo C. ERβ overexpression results in endocrine therapy resistance and poor prognosis in postmenopausal ER ɑ-positive breast cancer patients. Oncology letters. 2016; 11 (2): 1531–1536. doi: 10.3892/ol.2016.4095.

22. Zhou Y., Liu X. The role of estrogen receptor beta in breast cancer. Biomark Res. 2020; 8 (39). doi: 10.1186/s40364-020-00223-2.

23. Hammond M.E., Hayes D. F., Dowsett M., Allred D.C., Hagerty K.L., Badve S. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010; 28 (21): 3543. J Clin Oncol. 2010; 28 (16): 2784–2795. doi: 10.1200/JCO.2009.25.6529.

24. Scholzen T., Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000; 182 (3): 311–322. doi: 10.1002/(SICI)1097-4652(200003)182:3<311:AID-JCP1>3.0.CO;2-9.

25. de Azambuja E., Cardoso F., de Castro G., Jr Colozza M., Mano M.S., Durbecq V. et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007; 96 (10): 1504–1513. doi: 10.1038/sj.bjc.6603756.

26. Luporsi E., André F., Spyratos F., Martin P.M., Jacquemier J., Penault-Llorca F. et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat. 2012; 132 (3): 895–915. doi: 10.1007/s10549-011-1837-z.

27. Bogush T.A., Basharina A.A., Eliseeva B.K., Kaliuzhny S.A., Bogush E.A., Kirsanov V.Y. et al. A new approach to epithelial-mesenchymal transition diagnostics in epithelial tumors: double immunofluorescent staining and flow cytometry. Biotechniques. 2020; 69 (4): 257–263. doi: 10.2144/btn-2020-0024.